Marco for Hospitals

Payers receive coverage requests for high-cost drugs for rare diseases and need to evaluate them with scientific rigor and in an auditable way within short timelines.

Hospitals need to demonstrate to accreditors and auditors that their therapeutic decisions follow current clinical guidelines, but lack systems to systematically track and document this compliance.

HEOR teams need to generate structured, comparable evidence for multiple HTA markets simultaneously, with limited resources and very tight timelines.

Governments lack visibility into the knowledge gaps and real therapeutic challenges of physicians in their public network, making it difficult to prioritize resources and training programs.

Oncology genomics labs want to differentiate themselves by delivering reports with greater clinical value, but lack the medical resources to write personalized clinical interpretations for each patient.

Hospitals need to integrate scientific evidence into the clinical workflow without disrupting existing processes or generating additional burden for the physician.